Multi-domain effectiveness of guselkumab evaluated via composite indices through 1 year in patients with PsA and inadequate response to TNFi: post hoc analysis of COSMOS by Gossec, L, Baraliakos, X, Aletaha, D, Sharaf, M, Rampakakis, E, Lavie, F, López-Medina, C, Selmi, C, Coates, LC

Modulation of interleukin-23 signaling with guselkumab in biologic-naive patients versus tumor necrosis factor inhibitor–inadequate responders with active psoriatic arthritis by Siebert, S, Coates, LC, Schett, G, Raychaudhuri, SP, Chen, W, Gao, S, Seridi, L, Chakravarty, SD, Shawi, M, Lavie, F, Sharaf, M, Zimmermann, M, Kollmeier, AP, Xu, XL, Rahman, P, Mease, PJ, Deodhar, A

Modulation of Interleukin‐23 Signaling With Guselkumab in Biologic‐Naive Patients Versus Tumor Necrosis Factor Inhibitor–Inadequate Responders With Active Psoriatic Arthritis by Siebert, S, Coates, LC, Schett, G, Raychaudhuri, SP, Chen, W, Gao, S, Seridi, L, Chakravarty, SD, Shawi, M, Lavie, F, Sharaf, M, Zimmermann, M, Kollmeier, AP, Xu, XL, Rahman, P, Mease, PJ, Deodhar, A